Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Receivables (2018 - 2022)

Ironwood Pharmaceuticals' Non-Current Receivables history spans 5 years, with the latest figure at $14.6 million for Q4 2022.

  • For Q4 2022, Non-Current Receivables fell 39.21% year-over-year to $14.6 million; the TTM value through Dec 2022 reached $14.6 million, down 39.21%, while the annual FY2022 figure was $14.6 million, 39.21% down from the prior year.
  • Non-Current Receivables for Q4 2022 was $14.6 million at Ironwood Pharmaceuticals, up from $14.4 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $32.6 million in Q4 2019 and bottomed at $14.1 million in Q1 2022.
  • The 5-year median for Non-Current Receivables is $23.2 million (2020), against an average of $22.1 million.
  • The largest annual shift saw Non-Current Receivables surged 55.22% in 2019 before it tumbled 39.98% in 2022.
  • A 5-year view of Non-Current Receivables shows it stood at $21.0 million in 2018, then soared by 55.22% to $32.6 million in 2019, then dropped by 28.21% to $23.4 million in 2020, then rose by 2.55% to $24.0 million in 2021, then crashed by 39.21% to $14.6 million in 2022.
  • Per Business Quant, the three most recent readings for IRWD's Non-Current Receivables are $14.6 million (Q4 2022), $14.4 million (Q3 2022), and $14.3 million (Q2 2022).